# Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 1356 BS in Healthy Male Volunteers

> **NCT02183298** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 36 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BI 1356 BS - intravenous
- **DRUG:** BI 1356 BS - Tablet
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02183298
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2006-07
- **Final completion:** —
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2014-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02183298

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02183298, "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 1356 BS in Healthy Male Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02183298. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*